Home-based intravenous treatment with reslizumab for severe asthma in the Netherlands - An evaluation.

Autor: Bendien SA; Dept of Respiratory Medicine, Haga Teaching Hospital, The Hague, the Netherlands. Electronic address: s.vannederveen@hagaziekenhuis.nl., van Leeuwen MM; Dept of Hospital Pharmacy, Haga Teaching Hospital, The Hague, the Netherlands. Electronic address: merlevanleeuwen@live.nl., Lau HS; Dept of Hospital Pharmacy, Franciscus Gasthuis & Vlietland, Rotterdam, the Netherlands. Electronic address: H.Lau@Franciscus.nl., Ten Brinke A; Dept of Respiratory Medicine, Medical Centre Leeuwarden, Leeuwarden, the Netherlands. Electronic address: a.tenbrinke@mcl.nl., Visser LE; Dept of Hospital Pharmacy, Haga Teaching Hospital, The Hague, the Netherlands; Dept of Hospital Pharmacy, Erasmus MC, Rotterdamn, the Netherlands; Dept of Epidemiology, Erasmus MC, Rotterdam, the Netherlands. Electronic address: l.e.visser@hagaziekenhuis.nl., de Koning EM; Dept of Hospital Pharmacy, Franciscus Gasthuis & Vlietland, Rotterdam, the Netherlands. Electronic address: eline_dekoning@live.nl., Braunstahl GJ; Dept of Respiratory Medicine, Franciscus Gasthuis & Vlietland, Rotterdam, the Netherlands; Department of Pulmonary Medicine, Erasmus MC, University Medical Center, Rotterdam, the Netherlands. Electronic address: g.braunstahl@franciscus.nl.

Publikováno v: Respiratory medicine [Respir Med] 2022 Apr; Vol. 194, pp. 106776. Date of Electronic Publication: 2022 Feb 23.

Nonclinical cardiovascular safety evaluation of romosozumab, an inhibitor of sclerostin for the treatment of osteoporosis in postmenopausal women at high risk of fracture.

Autor: Turk JR; Translational Safety and Bioanalytical Sciences, Amgen Research, Thousand Oaks, CA, USA. Electronic address: jturk@amgen.com., Deaton AM; Translational Safety and Bioanalytical Sciences, Amgen Research, Cambridge, MA, USA., Yin J; Genome Analysis Unit, Amgen Research, South San Francisco, CA, USA., Stolina M; Cardiometabolic Disorders Research, Amgen Research, Thousand Oaks, CA, USA., Felx M; Charles River Laboratories Montreal ULC, Senneville, QC, Canada., Boyd G; Charles River Laboratories Montreal ULC, Senneville, QC, Canada., Bienvenu JG; Charles River Laboratories Montreal ULC, Senneville, QC, Canada., Varela A; Charles River Laboratories Montreal ULC, Senneville, QC, Canada., Guillot M; Charles River Laboratories Montreal ULC, Senneville, QC, Canada., Holdsworth G; UCB Pharma, Slough, UK., Wolfreys A; UCB Pharma, Slough, UK., Dwyer D; Cardiometabolic Disorders Research, Amgen Research, Thousand Oaks, CA, USA., Kumar SV; Translational Safety and Bioanalytical Sciences, Amgen Research, Cambridge, MA, USA., de Koning EM; Translational Safety and Bioanalytical Sciences, Amgen Research, Cambridge, MA, USA., Qu Y; Translational Safety and Bioanalytical Sciences, Amgen Research, Thousand Oaks, CA, USA., Engwall M; Translational Safety and Bioanalytical Sciences, Amgen Research, Thousand Oaks, CA, USA., Locher K; Translational Safety and Bioanalytical Sciences, Amgen Research, South San Francisco, CA, USA., Ward LD; Translational Safety and Bioanalytical Sciences, Amgen Research, Cambridge, MA, USA., Glaus C; Cardiometabolic Disorders Research, Amgen Research, Thousand Oaks, CA, USA., He YD; Translational Safety and Bioanalytical Sciences, Amgen Research, Thousand Oaks, CA, USA; Genome Analysis Unit, Amgen Research, South San Francisco, CA, USA., Boyce RW; Translational Safety and Bioanalytical Sciences, Amgen Research, Thousand Oaks, CA, USA.

Publikováno v: Regulatory toxicology and pharmacology : RTP [Regul Toxicol Pharmacol] 2020 Aug; Vol. 115, pp. 104697. Date of Electronic Publication: 2020 Jun 23.